Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Publication | Open Access

DOI Full Paper Access

126

Citations

References

2015

Year

Javier Cortés, Véronique Dièras, Jungsil Ro, Jérôme Barrière, Thomas Bachelot, Sara A. Hurvitz, Émilie Le Rhun, Marc Espié, Sung‐Bae Kim, Andreas Schneeweiß,

The Lancet Oncology

Breast OncologyOncologyHealth SciencesLux-breast 3Clinical TrialsBreast CancerCancer TreatmentProgressive Brain MetastasesMedicineRadiation OncologyHer2-positive Breast Cancer